Quick Answer
Zentalis Pharmaceuticals, Inc. reported R&D Expense of $107.30 million for fiscal year 2025.
Zentalis Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $107.30M | -36.0% |
| 2024 | $167.77M | -11.5% |
| 2023 | $189.59M | +9.8% |
| 2022 | $172.73M | -1.6% |
| 2021 | $175.60M | +106.8% |
| 2020 | $84.90M | +121.2% |
| 2019 | $38.39M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.95M | -37.7% | -16.9% |
| June 30, 2025 | $27.61M | -42.9% | +1.3% |
| March 31, 2025 | $27.25M | -45.0% | -26.0% |
| September 30, 2024 | $36.82M | -21.3% | -23.9% |
| June 30, 2024 | $48.39M | +13.4% | -2.4% |
| March 31, 2024 | $49.59M | +2.1% | +6.0% |
| September 30, 2023 | $46.77M | +10.9% | +9.6% |
| June 30, 2023 | $42.68M | -2.6% | -12.1% |
- Zentalis Pharmaceuticals, Inc. showed a decrease of -36.0% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Zentalis Pharmaceuticals, Inc.’s r&d expense has grown by 179.5% (from $38.39 million to $107.30 million).
- The most recent figure is from Zentalis Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: